Research-grade compound. Laboratory use only. Not intended for human or animal use, ingestion, or injection. No medical claims are made or implied.
≥98% PuritySupplier batch spec · ≥98% (class spec)
Endocrine and Hormone Research PeptidesSKU: CP-TES
Tesamorelin
≥98% PuritySupplier batch spec; selected lots Janoshik-tested
Related PeptidesDB entry (same owner)
peptidesdb.org
/p/tesamorelin
Delivers to EU in 3-7 business days
Free shipping over €200 · no customs paperwork (EU) · via EU carrier network
Size2mg
€22.99
1
Total: €22.99
Free shipping on orders over €200
Research-grade Tesamorelin. ≥98% supplier batch specification; selected lots independently tested (99.3% avg across published reports). Lyophilized powder in sealed glass vial. For laboratory research use only. Not for human consumption.
Volume PricingApplied automatically at checkout
| Quantity | Price Each | Total | Savings |
|---|---|---|---|
| 1 unit | €43.49 | €43.49 | -- |
| 3+ | €41.32 | €123.95 | 5% off |
| 5+Most Popular | €39.14 | €195.71 | 10% off |
| 10+ | €36.97 | €369.67 | 15% off |
Important Notice
This product is intended for laboratory and research use only. Not for human or veterinary use. By purchasing, you confirm this product will be used exclusively for in-vitro research purposes.
Reconstitution Required
This peptide ships lyophilized (dry powder) and requires bacteriostatic water to reconstitute before use. BAC water is sold separately.
When This Product May Not Suit Your Research
- ⚠If your research requires GMP-grade material for clinical applications — research-grade peptides are not intended for clinical use.
- ⚠If your lab lacks proper cold storage (-20°C freezer) — this peptide's stability may be compromised at higher temperatures.
- ⚠If your study protocol requires FDA-approved reference standards — contact USP or a certified reference material provider.
Purity HPLC
99.2% average HPLC purity, verified by independent third-party testing
Third-Party Tested
Janoshik report published when available
Fast Shipping
24h dispatch, EU-wide shipping from €4.99
Third-Party Tested
Supplier batch specification on every product; independent Janoshik report on selected lots
Last reviewed: 2026-07-18
About Tesamorelin
For research purposes only. Not for human or veterinary use. Not a drug, food, or cosmetic.
Overview
Tesamorelin is a synthetic analog of the full-length human growth-hormone-releasing hormone, GHRH(1–44), carrying a trans-3-hexenoic acid group at the N-terminus that increases receptor-binding stability relative to unmodified GHRH. CAS 218949-48-5; molecular weight 5,135.9 Da. It is one of the most thoroughly characterised GHRH analogs available, which is precisely why researchers reach for it: the supporting pharmacology and clinical-research dataset is deeper than for shorter analogs such as sermorelin (1–29) or CJC-1295.
Mechanistically, tesamorelin follows standard GHRH biology. In research models, activation of the pituitary GHRH receptor is studied for its role in pulsatile GH secretion, downstream IGF-1 signalling, and GH-mediated lipolysis that appears to preferentially engage visceral adipose depots. Tesamorelin is a stabilized analog of the full 44-amino-acid growth-hormone-releasing hormone sequence, carrying an N-terminal modification associated with increased resistance to enzymatic cleavage. CertaPeptides is a reseller and supplies tesamorelin as a research reagent; we do not manufacture or formulate it, and the salt form is as supplied by our source.
Research Areas
The literature around tesamorelin generated endpoints that go well beyond GH and IGF-1, which is what distinguishes it as a research reference compound. A randomised trial in patients with HIV-associated abdominal fat accumulation investigated the metabolic effects of this growth-hormone-releasing factor, using visceral adipose tissue as a measured endpoint (Falutz et al., 2007). A later randomised study examined effects on both visceral fat and liver fat, quantifying hepatic fat as a distinct outcome (Stanley et al., 2014). That combination — MRI-measured visceral adiposity plus liver-fat quantification — is more developed for tesamorelin than for other GHRH analogs, which is why it recurs in visceral-adiposity, NAFLD-model, and metabolic-pathway research. For studies requiring a well-characterised GHRH reference, tesamorelin is the appropriate choice.
Specifications
| Molecular Weight | 5,135.9 Da |
|---|---|
| CAS | 218949-48-5 |
| Purity | ≥98% (supplier batch specification) |
| Form | Lyophilized powder |
| Sizes | 2mg, 5mg, 10mg, 20mg |
| Storage | −20°C lyophilized; 2–8°C after reconstitution, use within 4 weeks |
Quality & Verification
Every unit ships to a ≥98% supplier batch specification. In addition, selected lots are independently tested by Janoshik Analytical (HPLC and mass spectrometry), and those reports are searchable by batch code at certapeptides.com/verify. We make no in-house testing claim and do not test every batch — the two-tier approach is intentional: a baseline supplier specification on all units, plus third-party reports on selected lots. EU-based handling and fulfilment under CERTALAB S.R.L.
Frequently Asked Questions
What makes tesamorelin different from sermorelin?
Sermorelin is GHRH(1–29) — the first 29 of the 44 residues. Tesamorelin is the full 44-amino-acid sequence with an N-terminal modification associated with increased stability. Tesamorelin also carries a far more developed research dataset, including visceral-fat and liver-fat endpoints that sermorelin lacks.
Why is tesamorelin associated with visceral fat research specifically?
In research models, tesamorelin's GH-driven lipolysis is studied for preferentially engaging visceral adipose tissue rather than subcutaneous depots. Trials characterising the compound used MRI-measured visceral fat as a primary endpoint (Falutz et al., 2007), which is why it features prominently in visceral-adiposity and metabolic-pathway investigation.
How is tesamorelin stored?
Keep the lyophilized powder at −20°C, away from light. After reconstitution, store at 2–8°C and use within about four weeks. As a full-length peptide it is sensitive to repeated temperature cycling, so minimise freeze-thaw of the reconstituted solution.
Why does the full 44-residue sequence matter?
Tesamorelin retains the full 44-amino-acid GHRH sequence with an N-terminal modification; the structural description here is limited to sequence and stability, not comparative potency claims.
What endpoints has tesamorelin research measured?
Beyond GH and IGF-1, the published research has measured MRI-quantified visceral adipose tissue, hepatic (liver) fat, and lipid/metabolic biomarkers (Stanley et al., 2014). This breadth of characterisation is what makes tesamorelin a useful reference tool for metabolic and adiposity research.
For research purposes only. Not for human consumption.
Specification Summary
Purity99.2% avg
FormLyophilized Powder
Storage-20\u00B0C
About Tesamorelin
For research purposes only. Not for human or veterinary use. Not a drug, food, or cosmetic.
Overview
Tesamorelin is a synthetic analog of the full-length human growth-hormone-releasing hormone, GHRH(1–44), carrying a trans-3-hexenoic acid group at the N-terminus that increases receptor-binding stability relative to unmodified GHRH. CAS 218949-48-5; molecular weight 5,135.9 Da. It is one of the most thoroughly characterised GHRH analogs available, which is precisely why researchers reach for it: the supporting pharmacology and clinical-research dataset is deeper than for shorter analogs such as sermorelin (1–29) or CJC-1295.
Mechanistically, tesamorelin follows standard GHRH biology. In research models, activation of the pituitary GHRH receptor is studied for its role in pulsatile GH secretion, downstream IGF-1 signalling, and GH-mediated lipolysis that appears to preferentially engage visceral adipose depots. Tesamorelin is a stabilized analog of the full 44-amino-acid growth-hormone-releasing hormone sequence, carrying an N-terminal modification associated with increased resistance to enzymatic cleavage. CertaPeptides is a reseller and supplies tesamorelin as a research reagent; we do not manufacture or formulate it, and the salt form is as supplied by our source.
Research Areas
The literature around tesamorelin generated endpoints that go well beyond GH and IGF-1, which is what distinguishes it as a research reference compound. A randomised trial in patients with HIV-associated abdominal fat accumulation investigated the metabolic effects of this growth-hormone-releasing factor, using visceral adipose tissue as a measured endpoint (Falutz et al., 2007). A later randomised study examined effects on both visceral fat and liver fat, quantifying hepatic fat as a distinct outcome (Stanley et al., 2014). That combination — MRI-measured visceral adiposity plus liver-fat quantification — is more developed for tesamorelin than for other GHRH analogs, which is why it recurs in visceral-adiposity, NAFLD-model, and metabolic-pathway research. For studies requiring a well-characterised GHRH reference, tesamorelin is the appropriate choice.
Specifications
| Molecular Weight | 5,135.9 Da |
|---|---|
| CAS | 218949-48-5 |
| Purity | ≥98% (supplier batch specification) |
| Form | Lyophilized powder |
| Sizes | 2mg, 5mg, 10mg, 20mg |
| Storage | −20°C lyophilized; 2–8°C after reconstitution, use within 4 weeks |
Quality & Verification
Every unit ships to a ≥98% supplier batch specification. In addition, selected lots are independently tested by Janoshik Analytical (HPLC and mass spectrometry), and those reports are searchable by batch code at certapeptides.com/verify. We make no in-house testing claim and do not test every batch — the two-tier approach is intentional: a baseline supplier specification on all units, plus third-party reports on selected lots. EU-based handling and fulfilment under CERTALAB S.R.L.
Frequently Asked Questions
What makes tesamorelin different from sermorelin?
Sermorelin is GHRH(1–29) — the first 29 of the 44 residues. Tesamorelin is the full 44-amino-acid sequence with an N-terminal modification associated with increased stability. Tesamorelin also carries a far more developed research dataset, including visceral-fat and liver-fat endpoints that sermorelin lacks.
Why is tesamorelin associated with visceral fat research specifically?
In research models, tesamorelin's GH-driven lipolysis is studied for preferentially engaging visceral adipose tissue rather than subcutaneous depots. Trials characterising the compound used MRI-measured visceral fat as a primary endpoint (Falutz et al., 2007), which is why it features prominently in visceral-adiposity and metabolic-pathway investigation.
How is tesamorelin stored?
Keep the lyophilized powder at −20°C, away from light. After reconstitution, store at 2–8°C and use within about four weeks. As a full-length peptide it is sensitive to repeated temperature cycling, so minimise freeze-thaw of the reconstituted solution.
Why does the full 44-residue sequence matter?
Tesamorelin retains the full 44-amino-acid GHRH sequence with an N-terminal modification; the structural description here is limited to sequence and stability, not comparative potency claims.
What endpoints has tesamorelin research measured?
Beyond GH and IGF-1, the published research has measured MRI-quantified visceral adipose tissue, hepatic (liver) fat, and lipid/metabolic biomarkers (Stanley et al., 2014). This breadth of characterisation is what makes tesamorelin a useful reference tool for metabolic and adiposity research.
For research purposes only. Not for human consumption.
Researcher Confidence
Why researchers choose CertaPeptides
Who actually tests this?
Selected lots are independently verified by Janoshik Analytical (Czech Republic) and published on the Janoshik public portal. Other lots ship with the supplier's batch specification. See /coa for the published wall.
View COAs →What if I get the wrong batch?
Every bottle label carries a lot number that maps to a specific Certificate of Analysis. If a batch fails spec, we don't ship it — full stop.
View COAs →Where does it ship from?
Romania (EU). We are CERTALAB SRL, CUI 54169956, VAT-registered. Sameday for Romania, GLS for most EU destinations, TCE Worldwide for the remaining cross-border EU and non-EU markets (UK, Switzerland, Norway, Iceland, Israel, Serbia). Delivery 1–15 business days depending on destination — exact window shown at checkout.
Shipping details →What if there's a problem?
You have a 14-day withdrawal right under OUG 34/2014 (Romanian/EU consumer law), with ANPC/ODR escalation available. Contact us at support@certapeptides.com.
Returns policy →Product Information
This product is intended for scientific research and development purposes only. It is a chemical substance that shall not be used as a drug, medicine, active substance, or ingredient in any product intended for human or animal consumption. Researchers must handle this compound in accordance with their institutional biosafety guidelines. Use only in properly equipped laboratory settings with appropriate personal protective equipment.
Frequently Asked
Research Library
Related Research Articles
Frequently researched together
Combined Price
€192.96
Tesamorelin€43.49